RESUMO
Our aims were to evaluate the clinical performance of human telomerase RNA gene component (hTERC gene) amplification assay with high-risk human papillomavirus (HR-HPV) DNA test of Hybrid Capture 2 DNA test (HC2), for the detection of high grade cervical precancerous lesions and cancer (CIN 2+). In addition, the association shown between hTERC gene amplification and HPV DNA test positive in women with and without cervical neoplasia was assessed. There were 92 women who underwent cytology, HR-HPV DNA test, hTERC gene amplification test, colposcopy and biopsy. We compared the clinical performance of hTERC gene test along with HR-HPV DNA test of women with colposcopy and routine screening. The samples were histology- confirmed high-grade cervical intraepithelial neoplasia (CIN 2) or worse (CIN2+) as the positive criterion. The test of hTERC gene showed the hTERC gene amplification positivity increased with the severity of histological abnormality and cytological abnormality. The test of hTERC gene showed higher specificity than HR-HPV DNA test for high-grade lesions (84.4% versus 50%) and also higher positive predictive value (90.4% versus 76.5%). Our results predicted that hTERC gene amplification demonstrated more specific performance for predicting the risk of progression and offer a strong potential as a tool for triage in cervical cancer screening, with the limited sensitive as HR-HPV DNA test.
Assuntos
Amplificação de Genes , Papillomaviridae/genética , Infecções por Papillomavirus/diagnóstico , Lesões Pré-Cancerosas/diagnóstico , RNA/genética , Telomerase/genética , Displasia do Colo do Útero/diagnóstico , Neoplasias do Colo do Útero/diagnóstico , Adulto , Idoso , Colposcopia , Estudos Transversais , Citodiagnóstico , DNA Viral/genética , Detecção Precoce de Câncer , Feminino , Seguimentos , Testes de DNA para Papilomavírus Humano , Humanos , Pessoa de Meia-Idade , Gradação de Tumores , Papillomaviridae/isolamento & purificação , Infecções por Papillomavirus/genética , Infecções por Papillomavirus/virologia , Lesões Pré-Cancerosas/genética , Lesões Pré-Cancerosas/virologia , Prognóstico , Neoplasias do Colo do Útero/genética , Neoplasias do Colo do Útero/virologia , Esfregaço Vaginal , Adulto Jovem , Displasia do Colo do Útero/genética , Displasia do Colo do Útero/virologiaRESUMO
OBJECTIVE: To assess prognostic factors impacted on overall survival in patients with epithelial ovarian carcinoma. METHODS: Totally 170 patients with stages I-IV epithelial ovarian carcinoma admitted in Shanxi Provincial Cancer Hospital from Jan 2002 to Dec 2005 were analyzed by retrospective analysis. RESULTS: The results showed that the prognostic factors of epithelial ovarian carcinomas were related to age, stage, histological type, pathological differential grade, the size of residues lesions and the number of course of chemotherapy (P < 0.01). The univariate analysis showed that family history was not related to the survival of epithelial ovarian carcinoma (P > 0.05). Compared with stage IV, the risk of mortality was 0.005 for stage I (95%CI, 0.001-0.024), 0.106 for stage II (95%CI, 0.038-0.297) and 0.361 (95%CI, 0.18-0.718) for stage III (P < 0.01). The risk of mortality was 0.307 (95%CI, 0.176-0.536) for the patients with residual diameter > 2 cm, in comparison with the residual < or = 2 cm (P < 0.01). The risk of mortality in patients received < 6 courses of chemotherapy was 8.191 times higher than that in patients received > or = 6 courses of chemotherapy (95%CI, 4.666 - 14.379; P < 0.01). CONCLUSIONS: The major independent prognostic variables for epithelial ovarian carcinoma are stage, the size of residual tumor lesions and the number of courses of chemotherapy. Therefore, the earlier diagnosis, the earlier surgery, sufficient cycles and timely assistant chemotherapy are the key point to improve the survival rates of epithelial ovarian carcinoma.
